- Home
- ARCH vs VRNA Comparison
ARCH vs VRNA Comparison
Compare ARCH & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARCH
- VRNA
- Stock Information
- Founded
- ARCH 1969
- VRNA 2005
- Country
- ARCH United States
- VRNA United Kingdom
- Employees
- ARCH N/A
- VRNA N/A
- Industry
- ARCH Coal Mining
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- ARCH Energy
- VRNA Health Care
- Exchange
- ARCH Nasdaq
- VRNA Nasdaq
- Market Cap
- ARCH 2.6B
- VRNA 2.9B
- IPO Year
- ARCH 1988
- VRNA 2017
- Fundamental
- Price
- ARCH $167.01
- VRNA $38.85
- Analyst Decision
- ARCH Buy
- VRNA Strong Buy
- Analyst Count
- ARCH 5
- VRNA 6
- Target Price
- ARCH $173.60
- VRNA $43.83
- AVG Volume (30 Days)
- ARCH 372.9K
- VRNA 1.1M
- Earning Date
- ARCH 11-05-2024
- VRNA 11-04-2024
- Dividend Yield
- ARCH 0.96%
- VRNA N/A
- EPS Growth
- ARCH N/A
- VRNA N/A
- EPS
- ARCH 9.67
- VRNA N/A
- Revenue
- ARCH $2,645,357,000.00
- VRNA $5,624,000.00
- Revenue This Year
- ARCH N/A
- VRNA N/A
- Revenue Next Year
- ARCH N/A
- VRNA $554.09
- P/E Ratio
- ARCH $17.38
- VRNA N/A
- Revenue Growth
- ARCH N/A
- VRNA 1127.95
- 52 Week Low
- ARCH $116.44
- VRNA $11.39
- 52 Week High
- ARCH $187.60
- VRNA $40.13
- Technical
- Relative Strength Index (RSI)
- ARCH 69.15
- VRNA 62.43
- Support Level
- ARCH $163.86
- VRNA $34.51
- Resistance Level
- ARCH $171.87
- VRNA $40.13
- Average True Range (ATR)
- ARCH 5.61
- VRNA 2.22
- MACD
- ARCH 0.33
- VRNA -0.17
- Stochastic Oscillator
- ARCH 85.95
- VRNA 85.00
About ARCH Arch Resources Inc.
Arch Resources Inc is a producer of metallurgical and coking coal. The company sells its coal to power plants, steel mills, and industrial facilities. Its operating segment includes Metallurgical (MET) and Thermal. It generates maximum revenue from the Metallurgical (MET) segment. Geographically, it derives a majority of its revenue from Asia.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.